Neovasc Inc. (NVCN) |
| 30.03 0 (0%) 04-10 16:00 |
| Open: | 29.59 |
| High: | 30.07 |
| Low: | 29.43 |
| Volume: | 1 |
| Market Cap: | 83(M) |
| PE Ratio: | -1.99 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 35.12 |
| Resistance 1: | 30.07 |
| Pivot price: | 29.82 |
| Support 1: | 29.43 |
| Support 2: | 29.04 |
| 52w High: | 30.07 |
| 52w Low: | 4.585 |
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.
Financials
| EPS | -15.070 |
| Book Value | 10.220 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Tue, 11 Apr 2023
Shockwave Medical (NDAQ:SWAV) completes Neovasc (TSX:NVCN) acquisition | 2023-04-11 | Investing News - Stockhouse
Wed, 18 Jan 2023
Shockwave Medical To Buy Neovasc: Details (NVCN) - Pulse 2.0
Tue, 17 Jan 2023
Shockwave to acquire Neovasc for up to $120M - BioWorld MedTech
Tue, 17 Jan 2023
Shockwave Medical Announces Agreement to Acquire Neovasc - GlobeNewswire
Tue, 08 Nov 2022
Neovasc Reducer Obtains U.S. Outpatient Reimbursement - Yahoo Finance
Mon, 14 Jun 2021
Neovasc pauses Tiara transfemoral mitral valve program, cuts workforce by 40% - BioWorld MedTech
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
